A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.

CONCLUSION: Dulaglutide is effective in the treatment of patients with type 2 diabetes but we need long follow-up data for safety concerns. PMID: 26316788 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26316788?dopt=Abstract

Source: Diabetes Metab - September 1, 2015 Category: Endocrinology Authors: Gurung T, Shyangdan DS, O'Hare JP, Waugh N Tags: Diabetes Metab Syndr Obes Source Type: research